Honors & Awards
Karen L. Campbell, PhD, Travel Support, American Society of Nephrology (2019)
Clinical Scientist in Nephrology Award, American Kidney Fund (2019)
Outstanding Resident Award, Rutgers/Saint Peter’s University Hospital (2018)
Innovation in Medicine Award, Rutgers/Saint Peter’s University Hospital (2018)
ASN Kidney STARS Award, American Society of Nephrology (2017)
Spring Clinical Meeting Travel Award, National Kidney Foundation (2017)
KIDNEYcon Travel Award, KIDNEYcon (2017)
Chief Resident, Internal Medicine, Rutgers/Saint Peter's University Hospital (2016-17)
Resident Appreciation Award, Rutgers/Saint Peters University Hospital (2016)
ASN Kidney STARS Award, American Society of Nephrology (2016)
Internal Medicine, Rutgers/Saint Peter's University Hospital (2017)
MD, Universidad San Carlos de Guatemala, Facultad de Ciencias Médicas (2012)
Screening for chronic kidney disease in a community-based diabetes cohort in rural Guatemala: a cross-sectional study.
2018; 8 (1): e019778
Screening is a key strategy to address the rising burden of chronic kidney disease (CKD) in low-income and middle-income countries. However, there are few reports regarding the implementation of screening programmes in resource-limited settings. The objectives of this study are to (1) to share programmatic experiences implementing CKD screening in a rural, resource-limited setting and (2) to assess the burden of renal disease in a community-based diabetes programme in rural Guatemala.Cross-sectional assessment of glomerular filtration rate (GFR) and urine albumin.Central Highlands of Guatemala.We enrolled 144 adults with type 2 diabetes in a community-based CKD screening activity carried out by the sponsoring institution.Prevalence of renal disease and risk of CKD progression using Kidney Disease: Improving Global Outcomes definitions and classifications.We found that 57% of the sample met GFR and/or albuminuria criteria suggestive of CKD. Over half of the sample had moderate or greater increased risk for CKD progression, including nearly 20% who were classified as high or very high risk. Hypertension was common in the sample (42%), and glycaemic control was suboptimal (mean haemoglobin A1c 9.4%±2.5% at programme enrolment and 8.6%±2.3% at time of CKD screening).The high burden of renal disease in our patient sample suggests an imperative to better understand the burden and risk factors of CKD in Guatemala. The implementation details we share reveal the tension between evidence-based CKD screening versus screening that can feasibly be delivered in resource-limited global settings.
View details for DOI 10.1136/bmjopen-2017-019778
View details for PubMedID 29358450
View details for PubMedCentralID PMC5781190
Treatment of end-stage renal disease with continuous ambulatory peritoneal dialysis in rural Guatemala.
BMJ case reports
A 42-year-old indigenous Maya man presented to a non-profit clinic in rural Guatemala with signs, symptoms and laboratory values consistent with uncontrolled diabetes. Despite appropriate treatment, approximately 18 months after presentation, he was found to have irreversible end-stage renal disease (ESRD) of uncertain aetiology. He was referred to the national public nephrology clinic and subsequently initiated home-based continuous ambulatory peritoneal dialysis. With primary care provided by the non-profit clinic, his clinical status improved on dialysis, but socioeconomic and psychological challenges persisted for the patient and his family. This case shows how care for people with ESRD in low- and middle-income countries requires scaling up renal replacement therapy and ensuring access to primary care, mental healthcare and social work services.
View details for DOI 10.1136/bcr-2017-223641
View details for PubMedID 29705734
View details for PubMedCentralID PMC5931272
Trends of Cannabis Use Disorder in the Inpatient: 2002 to 2011.
The American journal of medicine
2017; 130 (6): 678–87.e7
The nationwide prevalence of cannabis use/abuse has more than doubled from 2002 to 2011. Whether the outpatient trend is reflected in the inpatient setting is unknown. We examined the prevalence and incidence of cannabis abuse/dependence as determined by discharge coding in a 10-year (2002-2011) National Inpatient Sample, as well as various trends among demographics, comorbidities, and hospitalization outcomes.Cannabis abuse/dependence was identified on the basis of International Classification of Diseases, 9th Revision, Clinical Modification codes 304.3* and 305.2* in adults aged 18 years or more. We excluded cases coded "in remission." National estimates of trends and matched-regression analyses were conducted.Overall, 2,833,567 (0.91%) admissions with documented cannabis abuse/dependence were identified, patients had a mean age of 35.12 ± 0.06 years, 62% were male, and there was an increasing trend in prevalence from 0.52% to 1.34% (P <.001). The mean Charlson Comorbidity Index was 0.47 ± 0.006, and inpatient mortality was 0.41%. All of the above demonstrated an increasing trend (P <.001). Mean length of stay was 6.23 ± 0.06 days. The top primary discharge diagnoses were schizoaffective/mood disorders, followed by psychotic disorders and alcoholism. Asthma prevalence in nontobacco smokers had a steeper increase in the cannabis subgroup than in the noncannabis subgroup (P = .002). Among acute pancreatitis admissions, cannabis abusers had a shorter length of stay (-11%) and lower hospitalization costs (-7%) than nonabusers.Cannabis abuse/dependence is on the rise in the inpatient population, with an increasing trend toward older and sicker patients with increasing rates of moderate to severe disability. Psychiatric disorders and alcoholism are the main associated primary conditions. Cannabis abuse is associated with increased asthma incidence in nontobacco smokers and decreased hospital resource use in acute pancreatitis admissions.
View details for DOI 10.1016/j.amjmed.2016.12.035
View details for PubMedID 28161344
A quality improvement project using statistical process control methods for type 2 diabetes control in a resource-limited setting.
International journal for quality in health care : journal of the International Society for Quality in Health Care
2017; 29 (4): 593–601
Quality improvement (QI) is a key strategy for improving diabetes care in low- and middle-income countries (LMICs). This study reports on a diabetes QI project in rural Guatemala whose primary aim was to improve glycemic control of a panel of adult diabetes patients.Formative research suggested multiple areas for programmatic improvement in ambulatory diabetes care.This project utilized the Model for Improvement and Agile Global Health, our organization's complementary healthcare implementation framework.A bundle of improvement activities were implemented at the home, clinic and institutional level.Control charts of mean hemoglobin A1C (HbA1C) and proportion of patients meeting target HbA1C showed improvement as special cause variation was identified 3 months after the intervention began. Control charts for secondary process measures offered insights into the value of different components of the intervention. Intensity of home-based diabetes education emerged as an important driver of panel glycemic control.Diabetes QI work is feasible in resource-limited settings in LMICs and can improve glycemic control. Statistical process control charts are a promising methodology for use with panels or registries of diabetes patients.
View details for DOI 10.1093/intqhc/mzx051
View details for PubMedID 28486632
- A Patient Navigation System to Minimize Barriers for Peritoneal Dialysis in Rural, Low-Resource Settings: Case Study From Guatemala. Kidney international reports 2017; 2 (4): 762–65
Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff.
BMC health services research
2017; 17 (1): 27
Access to low-cost essential generic medicines is a critical health policy goal in low-and-middle income countries (LMICs). Guatemala is an LMIC where there is both limited availability and affordability of these medications. However, attitudes of physicians and pharmacy staff regarding low-cost generics, especially generics for non-communicable diseases (NCDs), have not been fully explored in Guatemala.Semi-structured interviews with 30 pharmacy staff and 12 physicians in several highland towns in Guatemala were conducted. Interview questions related to perceptions of low-cost generic medicines, prescription and dispensing practices of generics in the treatment of two NCDs, diabetes and hypertension, and opinions about the roles of pharmacy staff and physicians in selecting medicines for patients. Pharmacy staff were recruited from a random sample of pharmacies and physicians were recruited from a convenience sample. Interview data were analyzed using a thematic approach for qualitative data as well as basic quantitative statistics.Pharmacy staff and physicians expressed doubt as to the safety and efficacy of low-cost generic medicines in Guatemala. The low cost of generic medicines was often perceived as proof of their inferior quality. In the case of diabetes and hypertension, the decision to utilize a generic medicine was based on multiple factors including the patient's financial situation, consumer preference, and, to a large extent, physician recommendations.Interventions to improve generic medication utilization in Guatemala must address the negative perceptions of physicians and pharmacy staff toward low-cost generics. Strengthening state capacity and transparency in the regulation and monitoring of the drug supply is a key goal of access-to-medicines advocacy in Guatemala.
View details for DOI 10.1186/s12913-017-1991-z
View details for PubMedID 28086866
View details for PubMedCentralID PMC5234139
- Navigating Bureaucracy: Accompanying Indigenous Maya Patients with Complex Health Care Needs in Guatemala HUMAN ORGANIZATION 2016; 75 (4): 305–14
Argininemia as a cause of severe chronic stunting in a low-resource developing country setting: a case report.
2016; 16 (1): 142
Argininemia is rare inborn error of metabolism which, when untreated, presents in late infancy with growth delay and developmental regression. In developed countries, argininemia is diagnosed early by newborn screening and is treated immediately with a protein-restricted diet. In developing countries, diagnosis may be delayed by the assumption that stunting is related to malnutrition alone.We describe the diagnosis and treatment of argininemia in a 60-month-old Kaqchikel Maya girl in rural Guatemala. The patient initially presented with severe stunting and developmental regression. The initial diagnosis of argininemia was made by a screening test in dried blood spots and confirmed with urine and serum amino acid profiles. The patient was treated with a low-protein diet using locally available foods, leading to significant improvement in her growth and development.This case demonstrates that the identification, diagnosis and treatment of IEM in developing countries are increasingly feasible, as well as ethically imperative. Providers working with malnourished children in developing countries should suspect IEM in malnourished children who do not respond to standard therapies.
View details for DOI 10.1186/s12887-016-0668-9
View details for PubMedID 27549856
View details for PubMedCentralID PMC4994184
Implementation and Outcomes of a Comprehensive Type 2 Diabetes Program in Rural Guatemala.
2016; 11 (9): e0161152
The burden of chronic, non-communicable diseases such as diabetes is growing rapidly in low- and middle-income countries. Implementing management programs for diabetes and other chronic diseases for underserved populations is thus a critical global health priority. However, there is a notable dearth of shared programmatic and outcomes data from diabetes treatment programs in these settings.We describe our experiences as a non-governmental organization designing and implementing a type 2 diabetes program serving Maya indigenous people in rural Guatemala. We detail the practical challenges and solutions we have developed to build and sustain diabetes programming in this setting.We conduct a retrospective chart review from our electronic medical record to evaluate our program's performance. We generate a cohort profile, assess cross-sectional indicators using a framework adapted from the literature, and report on clinical longitudinal outcomes.A total of 142 patients were identified for the chart review. The cohort showed a decrease in hemoglobin A1C from a mean of 9.2% to 8.1% over an average of 2.1 years of follow-up (p <0.001). The proportions of patients meeting glycemic targets were 53% for hemoglobin A1C < 8% and 32% for the stricter target of hemoglobin A1C < 7%.We first offer programmatic experiences to address a gap in resources relating to the practical issues of designing and implementing global diabetes management interventions. We then present clinical data suggesting that favorable diabetes outcomes can be attained in poor areas of rural Guatemala.
View details for DOI 10.1371/journal.pone.0161152
View details for PubMedID 27583362
View details for PubMedCentralID PMC5008811